137 results about "Membrane vesicle" patented technology

The invention relates to a curcumin-loaded MMP response type melittin nano-pellicle vesicle as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. The preparation method comprises the following steps: firstly, preparing curcumin entrapped lipidosome; then carrying out culture amplification on engineering bacteria carrying melittin recombinant plasmids, extracting cell membranes after removing cell walls, and carrying out ultrasonic treatment and membrane extrusion to obtain melittin cell membrane nano-vesicles; fusing the curcumin lipidosome and the cell membrane nano-vesicles in an ultrasonic extrusion mode to obtain fused vesicles; and finally, carrying out surface calcium phosphate mineralization treatment on the fused vesicles to obtain the curcumin-loaded MMP response type melittin nano pellicle vesicles. The nano mycofilm vesicle prepared by the invention can be used for preparing antitumor drugs, and the biocompatibility and in-vivo stability of nanoparticles are improved by introducing a calcium phosphate coating; through combined delivery of melittin and curcumin, the anti-tumor effect is enhanced, so that the growth and proliferation of tumor cells are inhibited.

The application discloses an oral nano-vaccine and a preparation method and application thereof, and relates to the technical field of immunology, and specifically discloses an oral nano-vaccine which comprises a nano-particle wrapped by a biomimetic bacterial membrane vesicle and an outer layer; the nano-particle comprises an antigen and a biodegradable polymer material; the biomimetic bacterial membrane vesicle comprises an ionizable flagellar lipoprotein, an immune adjuvant, a phospholipid, a sterol lipid and a polyethylene glycol lipid; and the outer layer is a pH-responsive polymer. The oral nano-vaccine provided by the application combines the immune activation advantages of natural bacterial membrane vesicles and the precise regulation characteristics of synthetic materials, significantly improves the transmembrane penetration capacity of the antigen in the intestinal epithelium and the overall activation effect of the mucosal immune system. The oral nano-vaccine provided by the application can protect the antigen and the immune adjuvant from degradation and realize precise release in the intestinal microenvironment; and the oral nano-vaccine significantly improves the bioavailability and safety of an oral tumor vaccine, and lays a key technical foundation for clinical transformation and large-scale production of the oral tumor vaccine.

Pharmaceutical compositions and preparation including outer membrane vesicles (OMVs) and at least one pharmaceutically acceptable carrier wherein said OMVs are native OMVs produced by the Gram-negative commensal bacteria Bacteroides.

The invention relates to the technical field of immunology, in particular to a haemophilus parasuis disease mucosal vaccine as well as a preparation method and application thereof.The haemophilus parasuis disease mucosal vaccine comprises serum type 4 haemophilus parasuis H0040LV4 and serum type 5 haemophilus parasuis H0014LV5 which are preserved in the China Center for Type Culture Collection (CCTCC) on November 10, 2025 and numbered as CCTCC M 20252516 and CCTCC M 20252517; the bivalent haemophilus parasuis bivalent outer membrane vesicle vaccine prepared by secreting outer membrane vesicles has a good immune protection effect on serum type 4 and type 5 haemophilus parasuis, and compared with a control group, pathological changes of tissues such as lungs and livers of a vaccine immune group are obviously relieved. The vaccine has good immunogenicity, can stimulate comprehensive immune response, induce the organism to generate remarkable specific mucosal immunity, and simultaneously induce cellular immunity and humoral immunity response, and has a wide application prospect.

Provided herein is a hypervesiculating Escherichia coli Nissle (ΔECHy) bacterium engineered to produce outer membrane vesicles (OMVs), said OMVs packaging a fusion peptide including cytolysin A (ClyA) and hyaluronidase (Hy). Also provided are methods of remodeling a tumor, methods of treating cancer, and pharmaceutical compositions including the engineered ΔECHy bacterium.

The present invention belongs to the field of microbiology, and particularly relates to membrane vesicles (MVs) isolated from bacteria, and an isolation and preparation system and method for the membrane vesicles, and applications of the membrane vesicles. The bacteria of the present invention comprise Gram-positive bacteria and Gram-negative bacteria. The invention uses ionizing irradiation to irradiate bacteria, and isolates and purifies the produced membrane vesicles. The membrane vesicles prepared can be used as a vaccine, a vaccine adjuvant and / or a pharmaceutical carrier. In addition, the present invention provides a biological composition comprising the membrane vesicles and inactivated bacteria. In addition, the present invention also provides a preparation system, and isolation and purification system for bacterial membrane vesicles and the corresponding method. The membrane vesicles obtained by using the system and method have high yield, high purity and easy to be industrialized.

The invention discloses an immune agonist and a preparation method thereof, and relates to the technical field of immune agonist preparation, and the preparation method of the immune agonist comprises the following specific steps: S1, preparing a double-target immune agonist monomer; s2, preparing a cationic liposome inner core; s3, biomimetic cell membrane coating; and S4, finished product detection. According to the immune agonist and the preparation method thereof, in the preparation process, a continuous flow microreactor is used for two-step synthesis of a double-target monomer, a segmented precise temperature control mode is matched with microwave strengthening, the reaction period can be shortened, efficient entrapment of the agonist is achieved through a micro-reaction technology, and the problems that a traditional batch method is low in entrapment efficiency and uneven in particle size are solved; in addition, MDC cell membrane extraction is conducted through differential centrifugation, the integrity of the membrane is guaranteed, active targeting of a CD11c marker on the surface of the MDC cell membrane is achieved through a cell biomimetic membrane, and after lipidosome and membrane vesicles with the volume ratio being 3: 1 are fused, the in-vitro BMDC binding rate is increased compared with that of naked lipidosome.

Provided herein are vesicular nanocatalysts decorated on their surface with enzymes, such as for industrial use. More particularly, the nanocatalysts include outer membrane vesicles (OMVs) presenting on their surface carbonic anhydrase or a functional fragment or derivative thereof. Uses, methods of manufacture, and compositions of the nanocatalysts are also disclosed herein.

The disclosure relates to anti-inflammatory, oxygen-scavenging membrane vesicles derived from bacteria with modified or absent lipopolysaccharide. The disclosure further relates to pharmaceutical and nutritional compositions comprising these vesicles, and methods of using the same. Methods include therapeutic treatment of diseases associated with gut oxygenation and inflammation, such as inflammatory bowel disease, as well as non-therapeutic methods for supporting gastrointestinal health, promoting a healthy inflammatory response, and maintaining a balanced gut microbiota.

The application relates to the field of triple-negative breast cancer treatment and relates to synthesis of an acid-responsive amphiphilic liposome and application of the acid-responsive amphiphilic liposome in tumor treatment. A chemotherapeutic drug, a phospholipid, cholesterol and a polyethylene glycolized lipid are dissolved in an organic solvent chloroform, vacuum rotary evaporation is carried out under certain temperature and rotation rate, a water phase is added for hydration, a polypeptide nanogold cluster solution is added for ultrasonic treatment, then crushing, molecular sieve screening, dialysis and ultrafiltration are carried out to obtain a pH-sensitive liposome; in the preparation process, the phospholipid spontaneously forms a kind of biological membrane-like phospholipid bilayer membrane vesicle in water, and the chemotherapeutic drug and the nanogold cluster are wrapped in the vesicle. The pH-sensitive liposome can target the triple-negative breast cancer tumor site through pH response, can improve the solubility of the chemotherapeutic drug, can realize high-efficiency treatment effect of the drug at a low dose, can obviously reduce the toxic side effect of the chemotherapeutic drug, and can realize effective treatment of the triple-negative breast cancer.

The present application provides a kind of protecting group B meningococcal infection outer membrane vesicle composition, the outer membrane vesicle composition is by lipopolysaccharide modified group B meningococcal outer membrane vesicle and the outer membrane vesicle of group B meningococcal bacterium expressing recombinant protein is composed.The outer membrane vesicle composition provided by the present application has better protective effect on group B meningococcal infection relative to single strain outer membrane vesicle, and is more suitable for use as vaccine.

This invention provides bfrA Single gene knockout or bfrA Genes and bfrB Double gene knockout of Neisseria gonorrhoeae and its applications involve the field of biotechnology. Research has found that... bfrA Single gene knockout and bfrA and bfrB Double gene knockout of Neisseria gonorrhoeae resulted in increased formation of vesicles on the outer membrane, disruption of the cell wall and cell membrane, reduced adhesion and invasion abilities, decreased bacterial activity, decreased ATP levels, and weakened ability to infect mice. Therefore, knocking out Neisseria gonorrhoeae... bfrA Gene or bfrA and bfrB The dual-gene assay can be used to prepare products for the production of gonococcal outer membrane vesicles and to construct low-pathogenic gonococcal models.

The invention belongs to the technical field of synthetic biology and fermentation engineering, and discloses an engineering bacterium for producing Indigoidine based on membrane vesicle engineering reinforced corynebacterium glutamicum and application of the engineering bacterium. According to the invention, the ncp1 gene of corynebacterium glutamicum is knocked out through a CRISPR-Cas12a gene editing technology, connection between cell walls and cell membranes is relieved, and a chassis strain of high-yield extracellular membrane vesicles (OMVs) is constructed; meanwhile, a recombinant expression vector is introduced, indigo synthetase BpsA is positioned and displayed on membrane vesicles by utilizing PorB anchoring protein, and activating enzyme Sfp is co-expressed. In fermentation production, a staged feeding and IPTG (isopropyl-beta-d-thiogalactoside) and Tween-80 dual induction strategy is adopted to promote thalli to express zymoprotein and release a large number of membrane vesicles at the same time. According to the method, the membrane vesicles are used as an extracellular microreactor, so that the'simultaneous synthesis and secretion 'of the indissolvable indigo is realized, the problems of cytotoxicity and metabolic inhibition caused by intracellular precipitation of the product are effectively solved, and the yield and extraction efficiency of the indigo are remarkably improved.

The present application relates to the technical field of biological pharmacy, in particular to a combined drug for treating colitis and application thereof, wherein the volume ratio of Coptis exosome and Salmonella outer membrane vesicle in the combined drug is 1-2:1-3; the concentration of the Coptis exosome and the Salmonella outer membrane vesicle is 9-11 mg / mL. The present application overcomes the limitation of single treatment strategy by innovatively combining the Coptis exosome and the Salmonella outer membrane vesicle, significantly improves the treatment effect, and avoids the side effects of existing drugs. The present application has lower treatment cost, is safer and has no drug resistance problem, and can provide a more effective, safe and economical treatment method for inflammatory diseases such as colitis.

The present application relates to the field of biological medicine, in particular to a sensitizing agent for constructing a neutrophilic asthma animal model, a construction method and application. The present application uses Haemophilus influenzae outer membrane vesicles and ovalbumin as a sensitizing agent to construct a neutrophilic asthma animal model, and the test results show that the level of neutrophils in the blood and lung lavage fluid of mice is significantly increased compared with the treatment of ovalbumin as a sensitizing agent alone. The constructed mouse neutrophilic asthma model can be used for the research on the mechanism of clinical neutrophilic asthma and the development of neutrophilic asthma drugs.

Disclosed are protocols for preparing cell-free extracts preparation protocols that are enriched in membrane vesicles and use of the disclosed extract in cell-free glycoprotein synthesis methods and platforms for increasing glycoprotein yields.

The invention provides a bacterial outer membrane vesicle based on genetic engineering modification as well as preparation and application thereof, and relates to the technical field of biological medicines. According to the invention, through a genetic engineering technology, a bacterial outer membrane protein ClyA from escherichia coli W3110 is combined with a tumor killing peptide KLAK, and a recombinant plasmid ClyA-KLAK-pGEX-6P-1 for expressing a ClyA-KLAK fusion protein is constructed; the plasmid is transformed into W3110 escherichia coli to realize endogenous expression of the fusion protein, and the engineered outer membrane vesicles C-KLAK-OMVs with anti-tumor activity are successfully prepared. On the basis that the original morphology of the bacterial outer membrane vesicle is reserved, the anti-tumor activity of KLAK is also reserved, migration and invasion of tumor cells HGC27 and MDA-MB-231 can be remarkably inhibited, and apoptosis of the tumor cells HGC27 and MDA-MB-231 is promoted; meanwhile, the medicine loading potential is realized; in addition, the C-KLAK-OMVs also improves the problem of insufficient stability of the KLAK peptide in serum, and provides a new thought and reference for targeted therapy of tumors.

The invention belongs to the technical field of targeted drug delivery, and particularly relates to a metal complex, a giant plasma membrane vesicle bionic delivery drug system based on the metal complex and a preparation method and application of the giant plasma membrane vesicle bionic delivery drug system based on the metal complex, and the structure of the drug system is shown as follows: a carrier-metal complex, the carrier comprises a giant plasma membrane vesicle GPMVs bionic carrier, the metal complex comprises a metal complex IrC8. According to the traditional Chinese medicine system disclosed by the invention, the huge plasma membrane vesicles GPMVs are taken as a carrier, and a complex is encapsulated, so that a multifunctional synergistic treatment effect of chemotherapy, two-photon photodynamic therapy and immune activation is realized; while the water solubility and the biocompatibility are remarkably improved, the active targeting enrichment of tumor tissues can be realized, the drug resistance bottleneck of the traditional anti-tumor drug is remarkably overcome, and the breakthrough improvement of the tumor killing effect is realized; the preparation method is simple, low in cost and easy to operate.

This invention provides a composition, preparation method, and application for preventing Helicobacter pylori infection. The composition comprises a mixture of outer membrane vesicles and a solution of *Ackermania pseudomallei* bacteria; the outer membrane vesicle mixture is composed of outer membrane vesicles of *Salmonella* mutant strain QS0074 and outer membrane vesicles of *Escherichia coli* Nissle 1917 at a weight ratio of 2:1; the weight-to-volume ratio of the outer membrane vesicle mixture to the *Ackermania pseudomallei* bacterial solution is 1 mg:1 mL. The composition obtained by this invention significantly outperformed the control group in challenge tests, demonstrating a highly effective preventive effect against Helicobacter pylori infection. Furthermore, the components of the composition of this invention exhibit significant synergistic effects in inducing secretory IgA levels in mice and inducing resistance to Helicobacter pylori infection, showing promising application prospects.

The invention belongs to the technical field of biological medicine, and discloses an enteritis targeted probiotic delivery system and a preparation method and application thereof, the system comprises: i) a recombinant plasmid for coding an anti-inflammatory functional protein, the plasmid comprising an anti-inflammatory peptide fragment, a surface protein modification and an antibiotic switch; ii) Escherichia coli chassis bacteria which are subjected to genetic engineering modification and have the capability of high yield of outer membrane vesicles; and iii) introducing the recombinant plasmid into the escherichia coli chassis bacterium to obtain a recombinant engineering bacterium. The delivery system disclosed by the invention can target intestinal inflammation parts, deliver anti-inflammatory proteins through the outer membrane vesicles, and specifically release anti-inflammatory factors in an inflammation microenvironment, so that intestinal inflammation response is relieved; according to the present invention, the method can achieve the precise targeting on the intestinal inflammation, can effectively control the remote delivery and the continuous secretion of the anti-inflammatory protein in space and time, has advantages of strong targeting property, lasting effect, small side effect and the like, and provides the new strategy for the safe and efficient treatment of the intestinal inflammation diseases.

The invention provides a preparation process of a soothing and repairing type mask, and belongs to the technical field of cosmetics, an intelligent response type cell bionic delivery system is adopted, macrophage membrane vesicles serve as a carrier, a composite repairing kernel, epicatechin gallate, a neuropeptide P substance antagonist and idebenone are wrapped, and by means of the inflammation chemotaxis of a macrophage membrane, the soothing and repairing type mask is prepared. According to the present invention, the active component can actively target the inflammation region, the phase change release core is provided in the weakly acidic microenvironment with the pH value of 5.0-6.0, the targeting property and the permeation efficiency of the active component can be improved, the bottleneck of the traditional passive diffusion can be broken through, and compared with the conventional liposome or nanoparticle, the active component can be accurately delivered to the inflammation core region, the permeation rate can be improved by several times, and the carrier can directly reach the problem core region; according to the method, the utilization rate of effective components is greatly increased, a micro-ecology-immunity-nerve-physical barrier multi-dimensional and systematic synergistic repair network is constructed, full-path fundamental repair from immediate relieving to root strengthening is achieved, and immediate relieving and long-term barrier repair effects are provided.

The invention discloses a composite microneedle with bacterial outer membrane vesicles loaded with active ingredients as well as a preparation method and application of the composite microneedle. The composite microneedle is prepared from the bacterial outer membrane vesicles and the active ingredients loaded in the bacterial outer membrane vesicles, the bacterial outer membrane vesicles are derived from mucus eubacterium, the active ingredient is cycloastragenol, and the composite microneedle has a transdermal delivery function and delivers the active ingredient to a target tissue in a targeted manner. The method comprises the following steps: firstly, encapsulating cycloastragenol into mucus eubacterium outer membrane vesicles through a co-incubation or active drug loading technology to form a composite nano-carrier; the EL-OMVs-CAG compound prepared by the invention has good biocompatibility and blood brain barrier penetrating ability, and can target a central nervous system, regulate the activity of microglial cells, inhibit neuroinflammatory response and reduce synaptic loss and neuronal apoptosis in a hippocampal region, so that cognitive function impairment caused by operation and anesthesia is improved.

The application provides a kind of tea polyphenol ester-RNA self-assembly and hybrid nanovesicle of probiotic outer membrane vesicle and preparation method thereof, which first adjusts the hydrophilicity and hydrophobicity of tea polyphenol EGC through molecular modification strategy, and the EGC palmitate obtained by modification can directly wrap RNA and self-assemble into tea polyphenol ester-RNA nanovesicle, which has superior encapsulation capacity. Further introduce OMVs as intestinal targeted delivery carrier and fuse with RNA-tea polyphenol nanovesicle to form a structure stable hybrid vesicle. The hybrid vesicle of the application ingeniously integrates the advantages of both sides: tea polyphenol ester-RNA nanovesicle ensures efficient encapsulation of RNA, and OMVs provide natural protection for its translocation through gastrointestinal tract, and promote intestinal cell uptake with its inherent bioadhesion. This strategy can effectively promote the encapsulation and stabilization of oral RNA delivery.

The present application relates to the technical field of biological medicine, and particularly relates to Pseudogulbenkiania soli, outer membrane vesicles thereof and application. The present application provides a new method for treating or preventing liver fibrosis and related diseases by using Pseudogulbenkiania soli Pseudochrobactrum saccharolyticum The extracellular membrane vesicles of Pseudogulbenkiania soli and cells derived therefrom can significantly reverse the increase of serum liver function indicators of CCl4-induced liver fibrosis mice, and significantly reduce the histopathological damage of liver tissue. At the same time, both of them can effectively inhibit the local inflammatory response of liver and reduce the expression level of inflammatory factors. The above results show that Pseudogulbenkiania soli and its outer membrane vesicles can significantly improve the liver function damage, histological lesions and inflammatory state caused by CCl4 by regulating the inflammatory signaling pathway, and provide new experimental evidence and potential strategy for microbial intervention of liver fibrosis.

Engineered Bacteroides thetaiotaomicron (Bt) strains, including deletion mutant strains, and methods of use thereof are provided. Methods of delivering a therapeutic compound to a gut microbiome of a subject include generating an engineered Bacteroides thetaiotaomicron (Bt) strain to overproduce outer membrane vesicles (OMVs); loading a target therapeutic compound into the OMVs; and colonizing the gut microbiome of the subject with the engineered Bt strain. In some embodiments, the subject has at least one of lactose intolerance, phenylketonuria, inflammatory bowel disease, and a chronic intestinal condition.

The present invention relates to the field of bioengineering, and specifically relates to a Bordetella pertussis strain with an increased outer membrane vesicle (OMV) yield, wherein a BP2992 gene in the strain is partially or completely inactivated. The present invention further relates to a method for producing the Bordetella pertussis strain and a method for producing OMVs by means of the Bordetella pertussis strain.

The invention relates to the technical field of drugs, in particular to a supramolecular nano-drug, a preparation method and application thereof, the supramolecular nano-drug comprises platelet membrane vesicles, and Ce6-AS is loaded in the platelet membrane vesicles. The invention constructs a platelet membrane camouflaged nano platform P (at) Ce6-AS, which can synergistically induce ferroptosis and photodynamic therapy (PDT) for targeted therapy of oral tongue squamous cell carcinoma.

The invention discloses an apatinib-immune synergistic nano-drug based on bacterial source vesicles as well as a preparation method and application of the apatinib-immune synergistic nano-drug. The nano-drug is Apatinib-MVs, and the nano-drug takes a membrane vesicle secreted by parabacteroides coumarini as a carrier to entrap an anti-angiogenesis drug apatinib; in-vitro anti-tumor experiment results show that the nano-drug can exert an efficient anti-tumor effect through a dual synergistic mechanism of inhibiting tumor angiogenesis and activating anti-tumor immune response at the same time.

The application provides an E. coli outer membrane vesicle targeting TLR2 receptor and a construction method thereof, and relates to the technical field of biological medicine. The application first constructs a ClyA-HLYV fusion protein, and successfully obtains a recombinant plasmid ClyA-HLYV-pGEX-6P-1 stably expressing the fusion protein through genetic engineering technology, and induces endogenous expression of the fusion protein in an E. coli W3110 strain, to prepare a targeted bacterial outer membrane vesicle (HLYV-OMVs) expressing the ClyA-HLYV fusion protein on the surface. The HLYV-OMVs prepared by the application not only retain the specific recognition ability of HLYV to the surface TLR2 receptor of breast cancer cells, but also have the potential to encapsulate drugs, realizing the dual functions of targeted recognition and drug delivery. In addition, the HLYV-OMVs effectively solve the key problem of long-acting time of HLYV single peptide in targeted application, have good stability, significantly accelerate the effect starting speed after HLYV combines with the receptor, and lay an important foundation for efficient targeted treatment of tumors.

An application of a Bacillus Calmette-Guérin (BCG)-based outer membrane vesicle (OMV) trained immunity inducer in preparation of an immunotherapeutic drug for sepsis is provided. The disclosure isolates and collects OMVs secreted by BCG bacteria to obtain a BCG-based OMV trained immunity inducer (designated as B-OMVs). The B-OMVs combines distinct advantages of both BCG and OMVs while circumventing their respective drawbacks. The developed B-OMVs exhibits characteristics such as being non-replicative, non-infectious, and of low toxicity, resulting in minimal impact on the organism and high safety. In addition, the B-OMVs demonstrates a more moderate yet effective immunomodulatory capacity. It can induce trained immunity, enhance the body's resistance to microbial infections, reduce the need for antibiotics, and more effectively improve the prognosis of sepsis.